Intriguingly, our previous studies on ERα-positive breast cancer cells demonstrated that, unlike E2, Res reduces NGB levels in this cellular context, making these cells more susceptible to chemotherapy-induced apoptosis, thus antagonizing the effects of E2 on ERα, which is the only ER subtype expressed in these cells [22]. This evidence concerns the gene ESR1 and breast carcinoma.